TrialSignal transduction and targeted therapy2026

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.

Linong Ji et al.PubMed ↗Publisher ↗

No numbers read from the abstract.